Reuters logo
Teva's migraine drug succeeds in late-stage study
May 31, 2017 / 12:33 PM / 4 months ago

Teva's migraine drug succeeds in late-stage study

May 31 (Reuters) - Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraine met the main goal in a late-stage study.

Patients treated with the drug, fremanezumab, experienced a statistically significant reduction in the number of monthly headache days over the 12-week period for both monthly and quarterly dosing regimens, the company said. (Reporting by Natalie Grover in Bengaluru; Editing by Arun Koyyur)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below